ONESOURCE Onesource Specialty Pharma Q4 FY25 results (Jan–Mar 2025) and concall
OneSource delivered a transformative FY25, characterized by a 30% revenue jump and a doubling of EBITDA. The company is successfully pivoting toward high-value Drug Device Combinations (DDC), with 50 projects currently in the pipeline. While FY26 is signaled as a 'transition year' due to the timing of patent expiries for Semaglutide, management remains highly confident in achieving its $400 million revenue target by FY28.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 393 | 426 |
| EBITDA | 142 | 183 |
| Net profit | -69 | 98 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
